HRP20201528T1 - Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama - Google Patents
Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama Download PDFInfo
- Publication number
- HRP20201528T1 HRP20201528T1 HRP20201528TT HRP20201528T HRP20201528T1 HR P20201528 T1 HRP20201528 T1 HR P20201528T1 HR P20201528T T HRP20201528T T HR P20201528TT HR P20201528 T HRP20201528 T HR P20201528T HR P20201528 T1 HRP20201528 T1 HR P20201528T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- immunoglobulin
- separate variable
- variable domain
- polypeptide according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197999 | 2015-12-04 | ||
| EP16808971.2A EP3383425B1 (en) | 2015-12-04 | 2016-12-02 | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
| PCT/EP2016/079575 WO2017093478A1 (en) | 2015-12-04 | 2016-12-02 | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201528T1 true HRP20201528T1 (hr) | 2020-12-11 |
Family
ID=54782606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201528TT HRP20201528T1 (hr) | 2015-12-04 | 2016-12-02 | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama |
Country Status (32)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014020233A2 (pt) | 2012-02-28 | 2017-07-04 | Irm Llc | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| PT3383425T (pt) * | 2015-12-04 | 2020-10-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US11033636B2 (en) * | 2017-05-31 | 2021-06-15 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| WO2019108806A1 (en) * | 2017-11-29 | 2019-06-06 | Board Of Regents Of The University Of Texas System | Compositions and methods for cancer therapy |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| AU2019297522B2 (en) * | 2018-07-05 | 2026-04-23 | Surrozen Operating, Inc. | Multi-specific Wnt surrogate molecules and uses thereof |
| WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| KR20210099614A (ko) | 2018-12-04 | 2021-08-12 | 노파르티스 아게 | Cd3에 대한 결합 분자 및 이의 용도 |
| US11578129B2 (en) | 2019-03-29 | 2023-02-14 | Boehringer Ingelheim International Gmbh | LRP5 and PD-1 antagonist anticancer combination therapy |
| CA3130663A1 (en) | 2019-03-29 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| CN114040926B (zh) | 2019-05-04 | 2025-07-29 | 印希比生物科学有限公司 | 结合cd123的多肽及其用途 |
| EP3966338A1 (en) * | 2019-05-08 | 2022-03-16 | Inhibrx, Inc. | Cd123 targeted immunotherapies |
| CN118909117A (zh) * | 2019-08-14 | 2024-11-08 | 安托拉诊疗公司 | 与lrp6蛋白结合的抗体及使用方法 |
| US20230183336A1 (en) * | 2019-08-14 | 2023-06-15 | Modmab Therapeutics Inc. | Antibodies that bind to lrp5 proteins and methods of use |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
| WO2021163490A1 (en) * | 2020-02-14 | 2021-08-19 | University Of Washington | Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| JPWO2023286854A1 (enExample) * | 2021-07-16 | 2023-01-19 | ||
| EP4646436A2 (en) * | 2023-01-05 | 2025-11-12 | Harpoon Therapeutics, Inc. | Trop2 targeting trispecific protein for treatment of cancer |
| CN116375851B (zh) * | 2023-03-03 | 2024-03-22 | 中国农业科学院兰州兽医研究所 | 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用 |
| WO2025100520A1 (ja) | 2023-11-10 | 2025-05-15 | ペプチドリーム株式会社 | ペプチド、ペプチド複合体、医薬組成物、細胞培養用組成物、及び医療用、診断用又は研究用に用いられる組成物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6528054B1 (en) * | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| US7622267B2 (en) * | 2006-05-30 | 2009-11-24 | Van Andel Research Institute | Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods |
| CN102537051B (zh) | 2006-06-08 | 2014-11-26 | 日本精工株式会社 | 具有密封圈的冲压外圈滚针轴承及其制造方法 |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| CN100428934C (zh) | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用 |
| US20100113339A1 (en) | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン．ヴェー． | 血清タンパク質と結合可能なペプチド |
| MX2010004761A (es) | 2007-11-02 | 2010-05-19 | Novartis Ag | Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6). |
| US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| CA2721202A1 (en) | 2008-04-17 | 2009-10-22 | Hilde Adi Pierrette Revets | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US8661423B2 (en) | 2009-05-01 | 2014-02-25 | Telcordia Technologies, Inc. | Automated determination of quasi-identifiers using program analysis |
| US8276148B2 (en) | 2009-12-04 | 2012-09-25 | International Business Machines Corporation | Continuous optimization of archive management scheduling by use of integrated content-resource analytic model |
| CA2777527C (en) | 2009-12-23 | 2020-06-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| PH12012501744A1 (en) | 2010-03-03 | 2021-08-09 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
| KR101899835B1 (ko) | 2010-03-24 | 2018-09-19 | 제넨테크, 인크. | 항-ｌｒｐ６ 항체 |
| MX2012012927A (es) * | 2010-05-06 | 2013-05-01 | Novartis Ag | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
| SG185416A1 (en) | 2010-05-06 | 2012-12-28 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| CA2812785A1 (en) * | 2010-10-20 | 2012-04-26 | Genentech, Inc. | Methods and compositions for modulating the wnt pathway |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| US8883735B2 (en) | 2011-11-04 | 2014-11-11 | Novartis Ag | Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs |
| JP5949270B2 (ja) | 2012-07-24 | 2016-07-06 | 富士通株式会社 | オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム |
| EP2888279A1 (en) * | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
| PT3383425T (pt) * | 2015-12-04 | 2020-10-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais |
-
2016
- 2016-12-02 PT PT168089712T patent/PT3383425T/pt unknown
- 2016-12-02 MA MA054648A patent/MA54648A/fr unknown
- 2016-12-02 DK DK16808971.2T patent/DK3383425T3/da active
- 2016-12-02 WO PCT/EP2016/079575 patent/WO2017093478A1/en not_active Ceased
- 2016-12-02 MX MX2018006760A patent/MX380414B/es unknown
- 2016-12-02 HR HRP20201528TT patent/HRP20201528T1/hr unknown
- 2016-12-02 TW TW105139826A patent/TWI734719B/zh active
- 2016-12-02 LT LTEP16808971.2T patent/LT3383425T/lt unknown
- 2016-12-02 HU HUE16808971A patent/HUE051777T2/hu unknown
- 2016-12-02 ES ES16808971T patent/ES2821099T3/es active Active
- 2016-12-02 MY MYPI2018000854A patent/MY200933A/en unknown
- 2016-12-02 UA UAA201807120A patent/UA122079C2/uk unknown
- 2016-12-02 RS RS20201124A patent/RS60823B1/sr unknown
- 2016-12-02 AU AU2016363787A patent/AU2016363787B2/en active Active
- 2016-12-02 SG SG11201804510PA patent/SG11201804510PA/en unknown
- 2016-12-02 PL PL16808971T patent/PL3383425T3/pl unknown
- 2016-12-02 JP JP2018528327A patent/JP6728355B2/ja active Active
- 2016-12-02 EP EP16808971.2A patent/EP3383425B1/en active Active
- 2016-12-02 PH PH1/2018/501155A patent/PH12018501155B1/en unknown
- 2016-12-02 MA MA43368A patent/MA43368B1/fr unknown
- 2016-12-02 SI SI201630953T patent/SI3383425T1/sl unknown
- 2016-12-02 KR KR1020187019053A patent/KR102802241B1/ko active Active
- 2016-12-02 PE PE2018001063A patent/PE20181515A1/es unknown
- 2016-12-02 AR ARP160103720A patent/AR106949A1/es unknown
- 2016-12-02 US US15/367,323 patent/US10597449B2/en active Active
- 2016-12-02 EP EP20184267.1A patent/EP3797790A1/en not_active Withdrawn
- 2016-12-02 CN CN201680071043.6A patent/CN108289943B/zh active Active
- 2016-12-02 EA EA201891331A patent/EA201891331A1/ru unknown
-
2018
- 2018-05-02 ZA ZA2018/02867A patent/ZA201802867B/en unknown
- 2018-05-03 IL IL259119A patent/IL259119B/en unknown
- 2018-05-23 CL CL2018001384A patent/CL2018001384A1/es unknown
- 2018-05-29 CO CONC2018/0005680A patent/CO2018005680A2/es unknown
- 2018-06-04 SA SA518391728A patent/SA518391728B1/ar unknown
-
2020
- 2020-02-12 US US16/788,329 patent/US11952418B2/en active Active
- 2020-07-01 JP JP2020113792A patent/JP2020178701A/ja not_active Withdrawn
- 2020-10-12 CY CY20201100958T patent/CY1123454T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506841A5 (enExample) | ||
| HRP20240767T1 (hr) | Cd3 vezujuća antitijela | |
| JP2018501197A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| HRP20250666T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| JP2016020389A5 (enExample) | ||
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| JP2017506217A5 (enExample) | ||
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| RU2012149227A (ru) | Биологические материалы, относящиеся к her3 | |
| JP2016539096A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2021513540A5 (enExample) | ||
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| MY198942A (en) | Anti-tau antibodies and methods of use | |
| JP2015501814A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2014158469A5 (enExample) | ||
| AR106949A1 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| HRP20211794T1 (hr) | Humana antitijela za pd-1 |